Collectively, activation of GATM may represent an efficient therapeutic approach for ccRCC harboring the PBRM1 mutation under ICIs by regulating creatine metabolism to enhance antitumor T cell immunity in the tumor microenvironment. The gene discussed is GATM; the disease is nonpapillary renal cell carcinoma.